LEDA LEME TALIB

(Fonte: Lattes)
Índice h a partir de 2011
26
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina
LIM/27 - Laboratório de Neurociências, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 10 de 22
  • article 19 Citação(ões) na Scopus
    Hippocampal serotonin depletion is related to the presence of generalized tonic-clonic seizures, but not to psychiatric disorders in patients with temporal lobe epilepsy
    (2015) FONSECA, Natascha C. da; JOAQUIM, Helena P. G.; TALIB, Leda L.; VINCENTIIS, Silvia de; GATTAZ, Wagner F.; VALENTE, Kette D.
    Objective: Previous studies suggest that concentration of serotonin ([5-HT]) plays a pathogenic role in various types of epilepsy inhibiting seizures. However, most have not considered the clinical variables of epilepsy, and all of these studies included small and heterogeneous samples with refractory epilepsy, regardless of etiology. In this work, we measured [5-HT]s in hippocampal tissues from a large series of patients with refractory temporal lobe epilepsy caused by hippocampal sclerosis who underwent epilepsy surgery and evaluated the relationship between [5HT] and epilepsy-related clinical variables and psychiatric disorders. Methods: We included 44 patients with refractory unilateral TLE-HS who underwent surgical treatment for epilepsy. Hippocampal samples were collected, and serotonin concentrations were measured with high-pressure liquid chromatography (HPLC). Results: Lower [5-HT]s were correlated with a history of GTC seizures (Student's t-test: p0.041). There were no differences in [5-HT]s according to the other clinical variables and the presence of psychiatric disorders. Significance: Our findings demonstrated that serotonin depletion in the hippocampus play an important role in some aspects of the severity of epilepsy (i.e., the presence of GTC seizures) in a homogeneous sample of patients with refractory temporal lobe epilepsy determined by hippocampal sclerosis, but not with the presence of psychiatric disorders.
  • conferenceObject
    Distinct Glycogen Synthase Kinase 3 beta and Phospholipase A2 Expression Profiles in Bipolar I and II Disorders
    (2016) ZANETTI, Marcus V.; MACHADO-VIEIRA, Rodrigo; JOAQUIM, Helena P. G.; CHAIM, Tiffany M.; SERPA, Mauricio H.; SOUSA, Rafael T. de; GATTAZ, Wagner F.; BUSATTO, Geraldo F.; TALIB, Leda L.
  • article 4 Citação(ões) na Scopus
    Increased platelet glycogen sysnthase kinase 3beta in first-episode psychosis
    (2018) JOAQUIM, Helena P. G.; ZANETTI, Marcus V.; SERPA, Mauricio H.; BILT, Martinus T. Van de; SALLET, Paulo C.; CHAIM, Tiffany M.; BUSATTO, Geraldo F.; GATTAZ, Wagner F.; TALIB, Leda L.
    Past studies have linked intracellular pathways related to psychotic disorders to the GSK3B enzyme. This study aimed to investigate GSK3B protein expression and phosphorylation in drug-naive first-episode psychosis patients (n = 43) at baseline and following symptom remission, and in healthy controls (n = 77). At baseline GSK3B total level was higher in patients (p < 0.001). In schizophrenia spectrum patients (n = 25) GSK3B total and phosphorylated levels were higher than in controls and patients with other non-affective psychotic disorders (n = 18) (p < 0.001; p = 0.027; p = 0.05 respectively). No enzyme changes were found after clinical remission. The implication of this finding for the biology of psychoses warrants further studies to clarify whether increased GSK3B may be useful as a biomarker for psychosis in general, and schizophrenia in particular.
  • article 7 Citação(ões) na Scopus
    Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study
    (2020) COSTA, Alana C.; JOAQUIM, Helena P. G.; FORLENZA, Orestes V.; GATTAZ, Wagner F.; TALIB, Leda L.
    The metabolomic profile of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) may suggest potential diagnostic biomarkers and provide information on the pathophysiology of dementia. Our aim was to quantify plasmatic metabolites of AD patients, MCI and controls. We investigated the metabolomic profile-using the AbsoluteIDQ (R) p180 assay-of 79 older adults with primary cognitive impairment (34 AD and 20 MCI) and 25 healthy elders (controls). A cluster analysis revealed that a combination C12-DC, C12 and PCaaC26:0 could differentiate the patients according to diagnostic. Future studies should combine metabolomic profiles with other biomarkers to identify diagnostic groups.
  • conferenceObject
    Anti-psychotic Treatment Decreased iPLA2 Activity in First Episode Drug Naive Patients (DNP)
    (2014) TALIB, Leda Leme; JOAQUIM, Helena P. G.; SERPA, Mauricio H.; BILT, Martinus Th van de; BUSATTO, Geraldo; ZANETTI, Marcus V.; GATTAZ, Wagner F.
  • article 17 Citação(ões) na Scopus
    Kynurenine is correlated with IL-1 beta in plasma of schizophrenia patients
    (2018) JOAQUIM, Helena P. G.; COSTA, Alana C.; GATTAZ, Wagner F.; TALIB, Leda Leme
    The etiology of schizophrenia is still unclear. It is well-known that pro-inflammatory cytokines are higher in schizophrenia patients since the first episode psychosis comparing to healthy controls. Inflammatory downstream cascades influence different cellular pathways, like the displacement of the tryptophan (TRP) metabolism to the production of kynurenine (KYN) instead of serotonin, which results in the generation of several neuro and immunoactive metabolites. The aim of this study was to determine TRP, KYN and IL-1 beta plasma levels in first-onset schizophrenia (n = 28) and healthy controls (n = 30). The plasmatic levels of TRP and KYN were decreased in schizophrenic patients (p = 0.004 and p = 0.002, respectively), but there was no difference in the ratio of KYN/TRP (p = 0.554) or either in IL-1 beta (p = 0.101). Positive correlation was observed between KYN and IL-1 beta only in the schizophrenia group (r = 0.461, p = 0.021). And, there was also positive correlation between KYN and Positive and Negative Symptoms Scale (PANSS) (r = 0.395, p = 0.037). There is no correlation between the other analytes and other parameters of PANSS. Although our results of KYN have been different than expected and there was no difference in the KYN/TRP ratio, we observed a positive correlation between IL-1 beta and KYN, corroborating findings that pro-inflammatory agents hold up the KYN pathway.
  • conferenceObject
    Increased Glycogen Synthase Kinase-3B (GSK3B) Expression in Platelets of First Onset Psychosis Non-affective Patients
    (2014) JOAQUIM, Helena P. G.; TALIB, Leda L.; BILT, Martinus Th van de; ZANETTI, Marcus V.; BUSATTO, Geraldo; SERPA, Mauricio H.; GATTAZ, Wagner F.
  • article 2 Citação(ões) na Scopus
    Increased PLA(2) activity in individuals at ultra-high risk for psychosis
    (2021) TALIB, Leda L.; COSTA, Alana C.; JOAQUIM, Helena P. G.; PEREIRA, Cicero A. C.; BILT, Martinus T. van de; LOCH, Alexandre A.; GATTAZ, Wagner F.
    Phospholipase A(2) is the main enzyme in the metabolism of membrane phospholipids. It comprises a family of enzymes divided into iPLA(2), cPLA(2) and sPLA(2). Studies have reported increased PLA(2) activity in psychotic patients, which suggests an accelerated breakdown of membrane phospholipids. In the present study we investigated whether increased PLA(2) activity is also present in individuals at ultra-high risk (UHR) for psychosis. One-hundred fifty adults were included in this study (85 UHR and 65 controls). UHR was assessed using the ""structured interview for prodromal syndromes"". PLA(2) activity was determined in platelets by a radio-enzymatic assay. We found in UHR individuals increased activities of iPLA(2) (p < 0.001) and cPLA(2) (p = 0.012) as compared to controls. No correlations were found between socio-demographic and clinical parameters and PLA(2) activity. Our findings suggest that increased PLA(2) activities may be useful as a biological risk-marker for psychotic disorders.
  • conferenceObject
    INCREASED GLYCOGEN SYNTHASE KINASE-3B (GSK-3B) EXPRESSION IN PLATELETS OF FIRST ONSET PSYCHOSIS NON-AFFECTIVE PATIENTS
    (2014) JOAQUIM, Helena P. G.; TALIB, Leda L.; ZANETTI, Marcus; BILT, Martinus van de; BUSATTO, Geraldo; SERPA, Mauricio; GATTAZ, Wagner
  • article 6 Citação(ões) na Scopus
    Reduced Annexin A3 in schizophrenia
    (2020) JOAQUIM, Helena P. G.; COSTA, Alana Caroline; SERPA, Mauricio Henriques; TALIB, Leda L.; GATTAZ, Wagner F.
    The cellular and molecular mechanisms underlying onset and development of schizophrenia have not yet been completely elucidated, but the association of disturbed neuroplasticity and inflammation has gained particular relevance recently. These mechanisms are linked to annexins functions. ANXA3, particularly, is associated to inflammation and membrane metabolism cascades. The aim was to determine the ANXA3 levels in first-onset drug-naive psychotic patients. We investigated by western blot the protein expression of annexin A3 in platelets of first-onset, drug-naive psychotic patients (diagnoses according to DSM-IV: 28 schizophrenia, 27 bipolar disorder) as compared to 30 age- and gender-matched healthy controls. Annexin A3 level was lower in schizophrenia patients as compared to healthy controls (p < 0.001) and to bipolar patients (p < 0.001). Twenty out of 28 schizophrenic patients had undetectable annexin A3 levels, as compared to none from the bipolar and none from the control subjects. ANXA3 was reduced in drug-naive patients with schizophrenia. ANXA3 affects neuroplasticity, inflammation and apoptosis, as well as it modulates membrane phospholipid metabolism. All these processes have been discussed in regard to the biology of schizophrenia. In face of these data, we feel that further studies with larger samples are warranted to investigate the possible role of reduced ANXA3 as a possible risk marker for schizophrenia.